Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | AR | P10275 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
| ▸ | IKBKB | O14920 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL1884154 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL9863653 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601461 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL14373318 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL8813577 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL24622562 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601462 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL570639 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL22962813 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL4447 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | claimed |
| EP-1143950-A3 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2002-05-15 | — | — | EP | claimed |
| EP-1143950-A2 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2001-10-17 | — | — | EP | claimed |
| WO-2000015202-A2 | TOPICAL APPLICATION PRODUCTS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 2000-03-23 | — | — | WO | claimed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1680076-B1 | PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR TREATING FINGERNAILS | BIOEQUAL AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070166249-A1 | Pharmaceutical and cosmetic formulations for treating fingernails | BIOEQUAL AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| EP-1680076-A1 | PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR TREATING FINGERNAILS | BioEqual AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005063777-A1 | BENZYLPHOSPHATE AND SUBSTITUTED BENZYLPHOSPHATE PRODRUGS FOR THE TREATMENT OF PULMONARY INFLAMMATION | CORUS PHARMA (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005018585-A1 | PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR TREATING FINGERNAILS | BIOEQUAL AG (CH) | 2005-03-03 | — | — | WO | disclosed |
| US-6740326-B1 | WATER-FREE TOPICAL APPLICATION COMPOSITION FOR TREATMENT OF NAIL DISEASES AND NAIL CARE CONSISTING OF ANTIMYCOTIC AGENT AND LOWER ALKYL ESTER OF LACTIC ACID, MALIC ACID, TARTARIC ACID OR CITRIC ACID AS PENETRATION PROMOTING CARRIER | BIOEQUAL AG (CH) | 2004-05-25 | — | — | US | disclosed |
| EP-1143950-A3 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2002-05-15 | — | — | EP | disclosed |
| EP-1143950-A2 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000015202-A2 | TOPICAL APPLICATION PRODUCTS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 2000-03-23 | — | — | WO | disclosed |
| EP-0956047-A1 | NEW CARRIER SYSTEMS | IPR-Institute for Pharmaceutical Research Riehen AG (CH) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998016251-A1 | NEW CARRIER SYSTEMS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 1998-04-23 | — | — | WO | disclosed |
| EP-0063368-B1 | PROCESS FOR THE PREPARATION OF PREGN-4-ENE-3,20-DIONE DERIVATIVES AND 17-ALPHA-ETHYNYL-17-BETA-TRIFLUOROACETOXY-GON-4-ENE-3-ONE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE LATTER COMPOUNDS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-07-25 | — | — | EP | disclosed |
| EP-0063368-A1 | Process for the preparation of pregn-4-ene-3,20-dione derivatives and 17-alpha-ethynyl-17-beta-trifluoroacetoxy-gon-4-ene-3-one derivatives, and pharmaceutical compositions containing the latter compounds | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | NR3C1 1099/4885HIF1A 251/4885CYP3A4 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.